WuXi AppTec plans to launch the 2026 H-share Incentive Trust Scheme, with a maximum total of HKD 2.5 billion.

Wuxi Pharmatech (Cayman) Co., Ltd. (603259.SH / 2359.HK) recently disclosed the “2026 H-Share Reward Trust Plan (Draft),” proposing to establish an H-share stock reward trust with a maximum total of HKD 2.5 billion to incentivize directors, supervisors, senior management, and core technical personnel and other eligible employees.

According to the draft, the core funding for this plan will come from the company’s own funds not exceeding HKD 2.5 billion, authorized by the shareholders’ general meeting and category shareholder meetings, and from H-shares repurchased on the Hong Kong Stock Exchange (treasury shares). These repurchased H-shares will be transferred to the plan trustee (Hong Kong Central Securities Trust Limited) to establish a trust, serving as the source of future reward shares. The grant of awards is closely linked to the company’s revenue target for 2026: if the revenue reaches RMB 51.3 billion (basic grant condition), up to 60% of the total plan amount (i.e., HKD 1.5 billion) can be granted; if revenue further reaches RMB 53 billion (additional grant condition), the full HKD 2.5 billion cap can be utilized.

Vesting of the awards will be carried out in multiple batches, mainly over a three- to four-year vesting period, and will be tied to the personal performance evaluation results of the selected participants. The plan specifically stipulates that the awards granted to related parties of the company (including Chairman Li Ge and other core management) shall not exceed 60% of the plan cap at only the basic condition, and shall not exceed 35% of the total cap when the additional condition is also met. The plan is subject to approval by the company’s shareholders’ meeting before implementation. This initiative aims to align employee interests with the company’s long-term development and shareholder interests through equity incentives, attracting, motivating, and retaining key talent.